fda compounding semaglutide warning october 2025 September 8, 2025: launches an import alert listing safe GLP-1 manufacturers – Partnership for Safe Medicines Diabetes advocacy group discourages use

Although there are some links between TMAO and MAFLD and administration of TMAO impairs liver function and increases hepatic triglyceride accumulation and lipogenesis in animal models, whether reducing TMAO concentrations could prevent MAFLD remains unclear due to lack of relevant studies

Because your doctor works for your insurance company , getting an "off-formulary" medication like Zepbound is harder than with other insurers

Q2: Can GLP-1 medications cause pancreatitis

This hearing will be held on June 2, 2026, for MDL 3163 (Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation)

Adams J, Baral M, Geis E, Mitchell J, Ingram J, Hensley A, et al